Shots: Supernus signs a definitive agreement to acquire Adamas for $8.10/ share in cash (~$400M) & 2 non-tradable CVR of ~$1.00 00/share in cash (~$50M) based on sales of GOCOVRI, […]readmore
Shots: Boston has entered into a definitive agreement to acquire Baylis for $1.75B up front. The transaction is anticipated to close in Q1’22 The acquisition will bolster Boston’s electrophysiology and […]readmore
Shots: Inotiv to acquire Plato BioPharma for $15.0M that consist of $10.0M in cash, $2.0M in Inotiv’s common shares (57,587) based on the average closing price for 20 trading-day period […]readmore
Shots: Merck to acquire Acceleron for $180/share in cash making a total equity value of ~$11.5B representing a premium of 2.6% to the stock’s closing price. The transaction is expected […]readmore
Shots: Alexion has exercised its option to acquire all remaining equity in Caelum for CAEL-101 which is currently being evaluated in P-III CARES clinical program that consists of 2 P-III […]readmore
Shots: GE has signed an agreement to acquire BK Medical for $1.45B in cash and is eligible to receive a high-single-digit return on invested capital within 5yrs. The transaction is […]readmore
Shots: The acquisition includes upfront, milestones, and other consideration payments. Abexxa will continue to operate in the Arlington The acquisition will allow Boehringer to access Abexxa’s expertise and capabilities in […]readmore
Shots: Boston currently holds ~16% equity stake in Devor & acquires the remaining 84% for ~$269M up front and ~$67M upon achievement of clinical & regulatory milestones. The transaction is […]readmore
Shots: The acquisition expands Novartis’ ophthalmology portfolio with the addition of Arctos’ pre-clinical optogenetics-based AAV gene therapy program and its technology The acquisition marks the Novartis commitment to identify optogenetics-based […]readmore
Shots: AbCellera acquires TetraGenetics in an all-cash transaction that includes up front, milestones based on the achievement of technical milestones related to the development of therapeutics The acquisition will combine […]readmore